Bristol Myers Squibb Presents Five-Year Camzyos Data at ESC Congress 2026

The pharmaceutical company showcased long-term efficacy and safety results for mavacamten in treating obstructive hypertrophic cardiomyopathy at a major cardiology conference.

29 Aug, 15:45 — 29 Aug, 15:45

Post Share

Sources

Showing 1 of 1 sources

morningstar2d ago

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026 - Morningstar

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026 Morningstar

Read full article →

Bristol Myers Squibb Presents Five-Year Camzyos Data at ESC Congress 2026

Sources

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026 - Morningstar

Related Stories

Nigeria Reports 4.43 Percent Economic Growth in Second Quarter

Hyundai Motor South Korean Union Approves New Wage Deal

South Korea Reports 68.7% Surge in August Exports Driven by Chips

Shein Prices Hong Kong IPO Below Top End of Range